EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 8-9 (Août–Septembre 2020) Med Sci (Paris), 36 8-9 (2020) 695-699 References
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 8-9, Août–Septembre 2020
Page(s) 695 - 699
Section Le Magazine
DOI https://doi.org/10.1051/medsci/2020139
Published online 21 August 2020
  1. Lange M, Joly F, Vardy J, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019 ; 30 : 1925–1940. [CrossRef] [PubMed] [Google Scholar]
  2. Joly F, Heutte N, Duclos B, et al. Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer. Eur Urol Focus 2016 ; 2 : 642–649. [CrossRef] [PubMed] [Google Scholar]
  3. Dempke WCM, Fenchel K, Uciechowski P, Dale SP, Second- and third-generation drugs for immuno-oncology treatment: The more the better?. Eur J Cancer 2017 ; 74 : 55–72. [CrossRef] [PubMed] [Google Scholar]
  4. Davila ML, Sadelain M, Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol 2016 ; 104 : 6–17. [CrossRef] [PubMed] [Google Scholar]
  5. Wick W, Hertenstein A, Platten M, Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 2016 ; 17 : e529–e541. [CrossRef] [PubMed] [Google Scholar]
  6. Joly F, Castel H, Tron L, et al. Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst 2020; 112 : 123–7. [CrossRef] [PubMed] [Google Scholar]
  7. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015 ; 16 : 522–530. [CrossRef] [PubMed] [Google Scholar]
  8. Cuzzubbo S, Belin C, Chouahnia K, et al. Assessing cognitive function in patients treated with immune checkpoint inhibitors: a feasibility study. Psychooncology 2018 ; 27 : 1861–1864. [CrossRef] [PubMed] [Google Scholar]
  9. McGinnis GJ, Friedman D, Young KH, et al. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget 2017 ; 8 : 9155–9173. [CrossRef] [PubMed] [Google Scholar]
  10. Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 2019 ; 25 : 1557–1563. [CrossRef] [PubMed] [Google Scholar]
  11. Touat M, Talmasov D, Ricard D, Psimaras D, Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 2017 ; 30 : 659–668. [CrossRef] [PubMed] [Google Scholar]
  12. Lange M, Castel H, Le Fel J, et al. How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancer. Neurosci Biobehav Rev 2019 ; 107 : 602–614. [CrossRef] [PubMed] [Google Scholar]
  13. Kostine M, Marabelle A, Schaeverbeke T, Kfoury M, Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité. Med Sci (Paris) 2019 ; 35 : 949–956. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Catros V., Les CAR-T cells, des cellules tueuses spécifiques d’antigènes tumoraux : de nouvelles générations pour le traitement des tumeurs solides. Med Sci (Paris) 2019 ; 35 : 316–326. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.